-
Ranibizumab
- indication:For the treatment of patients with neovascular (wet) age-related macular degeneration.
- pharmacologypharmacology:
- mechanism: Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF<sub>110</sub>. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
- toxicity:
- absorprion:
- halflife: Approximately 3 days
- roouteelimination:
- volumedistribution:
- clearance: